Case Report: Exceptional Response to Nivolumab Plus Ipilimumab in a Young Woman With TFE3-SFPQ Fusion Translocation-Associated Renal Cell Carcinoma

Overview of attention for article published in Frontiers in oncology, December 2021

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (64th percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

So far, Altmetric has seen 13 X posts from 6 X users, with an upper bound of 23,282 followers.

RT @LaraHarikMD: Small steps in the right direction in the fight against translocation Associated renal cell carcinoma #gu #gupath #RenalCa…

RT @FrontOncology: Case Report: Exceptional Response to Nivolumab Plus Ipilimumab in a Young Woman With TFE3-SFPQ Fusion Translocation-Asso…

Small steps in the right direction in the fight against translocation Associated renal cell carcinoma #gu #gupath #RenalCancer @bilenma @virajmaster @DylanJMartini

Case Report: Exceptional Response to Nivolumab Plus Ipilimumab in a Young Woman With TFE3-SFPQ Fusion Translocation-Associated #RenalCellCarcinoma 💉 👨‍⚕️👩‍⚕️ @DylanJMartini et al 👉 https://t.co/633z7mUFdv @LaraHarikMD @virajmaster @HaydnKissick @bilenma

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 9 additional X posts.